Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc.

NASDAQ:CRBU

Overview | Financials
Company Name Caribou Biosciences, Inc.
Symbol CRBU
Currency USD
Price 1.8
Market Cap 162,994,860
Dividend Yield 0%
52-week-range 1.5 - 8.33
Industry Biotechnology
Sector Healthcare
CEO Dr. Rachel E. Haurwitz Ph.D.
Website https://cariboubio.com

An error occurred while fetching data.

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial

Related Stocks

ANI Pharmaceuticals, Inc. logo

ANI Pharmaceuticals, Inc.

ANIP

53.35 USD

Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

1.1 USD

Inhibrx, Inc. logo

Inhibrx, Inc.

INBX

14.6 USD

Cullinan Oncology, Inc. logo

Cullinan Oncology, Inc.

CGEM

11.6 USD

Aura Biosciences, Inc. logo

Aura Biosciences, Inc.

AURA

8.2 USD

Intercept Pharmaceuticals, Inc. logo

Intercept Pharmaceuticals, Inc.

ICPT

19 USD

Nano-X Imaging Ltd. logo

Nano-X Imaging Ltd.

NNOX

6.76 USD

Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc.

TNGX

3.1 USD

Financials

Numbers are in millions USD

Numbers are in millions USD